MX343205B - Peptidomiméticos de horquilla beta como antagonistas de cxc4. - Google Patents

Peptidomiméticos de horquilla beta como antagonistas de cxc4.

Info

Publication number
MX343205B
MX343205B MX2013014229A MX2013014229A MX343205B MX 343205 B MX343205 B MX 343205B MX 2013014229 A MX2013014229 A MX 2013014229A MX 2013014229 A MX2013014229 A MX 2013014229A MX 343205 B MX343205 B MX 343205B
Authority
MX
Mexico
Prior art keywords
cys11
xaa14
xaa13
xaa8
xaa7
Prior art date
Application number
MX2013014229A
Other languages
English (en)
Other versions
MX2013014229A (es
Inventor
Obrecht Daniel
Otto Gombert Frank
Zimmermann Johann
Original Assignee
Polyphor Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ag filed Critical Polyphor Ag
Publication of MX2013014229A publication Critical patent/MX2013014229A/es
Publication of MX343205B publication Critical patent/MX343205B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Analytical Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a los peptidomiméticos de ß-horquilla del ciclo fórmula general (Tyr1-His2-Xaa3-Cys4-Ser5-Al a6-Xaa7-Xaa8-Arg9-Tyr10-Cys11-Tyr12-Xaa13-Xaa14-DPro15-Pro16-), disulfuro de enlace entre Cys4 y Cys11 y sales farmacéuticamente aceptables de los mismos, Xaa3, Xaa7, Xaa8, Xaa13 y Xaa14 siendo residuos de aminoácidos de ciertos tipos que se definen en la descripción y las reivindicaciones, tienen propiedades farmacológicas favorables y pueden usarse para la prevención de infecciones por VIH en individuos saludables o para desacelerar y detener la progresión viral en pacientes infectados o en lugares en donde está mediada por el cáncer o como resultado de la actividad del receptor CXCR4 o en lugares en donde es mediada por enfermedades inmunológicas o como resultado de la actividad del receptor CXCP4, o para el tratamiento de inmunosupresión, o durante las recolecciones de aféresis de células madre de sangre periférica y/o como agentes para inducir la movilización de las células madre para regular la reparación de tejidos. Estos peptidomiméticos pueden ser fabricados por un proceso que se basa en una estrategia sintética mezclada en fase sólida y en solución.
MX2013014229A 2011-06-07 2012-06-06 Peptidomiméticos de horquilla beta como antagonistas de cxc4. MX343205B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2011059402 2011-06-07
PCT/EP2012/060763 WO2012168336A1 (en) 2011-06-07 2012-06-06 Beta - hairpin peptidomimetics as cxc4 antagonists

Publications (2)

Publication Number Publication Date
MX2013014229A MX2013014229A (es) 2014-01-23
MX343205B true MX343205B (es) 2016-10-28

Family

ID=46208595

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014229A MX343205B (es) 2011-06-07 2012-06-06 Peptidomiméticos de horquilla beta como antagonistas de cxc4.

Country Status (12)

Country Link
US (2) US9079939B2 (es)
JP (1) JP5957521B2 (es)
KR (1) KR102091456B1 (es)
CN (1) CN103703018B (es)
AU (1) AU2012266355B2 (es)
BR (1) BR112013031575B1 (es)
CA (1) CA2838037C (es)
ES (1) ES2552944T3 (es)
IL (1) IL229535B (es)
MX (1) MX343205B (es)
SG (1) SG195055A1 (es)
WO (1) WO2012168336A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007079597A1 (en) 2006-01-16 2007-07-19 Polyphor Ltd. Template - fixed peptidomimetics with antimicrobial activity
CN101641372B (zh) 2007-02-28 2012-11-28 波利弗尔有限公司 模板固定的肽模拟物
CN104603145B (zh) 2012-06-06 2018-05-18 波利弗尔股份公司 β-发夹肽模拟物
IL302979A (en) 2020-11-19 2023-07-01 Spexis Ag Pharmaceutical combinations containing peptide CXCR4 inhibitor and taxane for cancer treatment
WO2022184320A2 (en) 2021-03-03 2022-09-09 Spexis Ag Medical use of cyclic peptides
WO2023285681A1 (en) 2021-07-16 2023-01-19 Spexis Ag Pharmaceutical combinations for treating cancer
WO2023285677A1 (en) 2021-07-16 2023-01-19 Spexis Ag Pharmaceutical combinations for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2136696C1 (ru) 1993-10-14 1999-09-10 Сейкагаку Корпорейшн Новый полипептид и фармацевтическая композиция против вич-инфекции
AU2003232253A1 (en) * 2003-05-02 2004-11-23 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity
CN101641372B (zh) * 2007-02-28 2012-11-28 波利弗尔有限公司 模板固定的肽模拟物
TWI423987B (zh) * 2007-05-30 2014-01-21 Lilly Co Eli 環肽ｃｘｃｒ４拮抗劑
WO2010060479A1 (en) * 2008-11-26 2010-06-03 Polyphor Ag Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity

Also Published As

Publication number Publication date
CN103703018A (zh) 2014-04-02
US20140213509A1 (en) 2014-07-31
KR20140041689A (ko) 2014-04-04
NZ618110A (en) 2014-12-24
ES2552944T3 (es) 2015-12-03
US9079939B2 (en) 2015-07-14
KR102091456B1 (ko) 2020-03-23
SG195055A1 (en) 2013-12-30
US20150266924A1 (en) 2015-09-24
CA2838037C (en) 2019-09-17
CN103703018B (zh) 2016-10-26
IL229535A0 (en) 2014-01-30
AU2012266355B2 (en) 2016-06-09
US9556231B2 (en) 2017-01-31
BR112013031575B1 (pt) 2021-03-16
BR112013031575A2 (pt) 2017-03-21
JP2014516999A (ja) 2014-07-17
IL229535B (en) 2018-07-31
CA2838037A1 (en) 2012-12-13
JP5957521B2 (ja) 2016-07-27
WO2012168336A1 (en) 2012-12-13
AU2012266355A1 (en) 2013-12-12
MX2013014229A (es) 2014-01-23

Similar Documents

Publication Publication Date Title
MX2014014840A (es) Peptido - mimeticos de la horquilla beta.
MX343205B (es) Peptidomiméticos de horquilla beta como antagonistas de cxc4.
MX2009008843A (es) Peptidomimeticos fijados a un patron.
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
PH12014502041A1 (en) Heterocyclyl compounds as mek inhibitors
ES2397889A1 (es) PÉPTIDOS MODULADORES DE PGC-1Alfa.
MX2020003055A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
EP3190186A3 (en) Expression of mirnas in placental tissue
JP2012041342A5 (es)
NZ608502A (en) Polypeptides that bind to human complement component c5
RU2013113184A (ru) Комбинированное лечение розацеа
MX354535B (es) TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß.
BR112012028437A2 (pt) solução oftálmica, e, método para tratar glaucoma ou hipertensão ocular
GB2546224A (en) Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
NZ600583A (en) Visfatin therapeutic agents for the treatment of acne and other conditions
EA201591108A1 (ru) Слитый гормон роста человека и альбумин, составы и их применения
WO2012177660A3 (en) Leukotoxin e/d as a new anti-inflammatory agent and microbicide
RU2014145351A (ru) КОМБИНАЦИЯ АНАЛОГОВ СОМАТОСТАТИНА С ИНГИБИТОРАМИ 11β-ГИДРОКСИЛАЗЫ
EA201591095A1 (ru) Белок slurp-1 для применения в лечении глазных болезней
CN104548194A (zh) 一种医用高性能粘合剂
MY166556A (en) Pharmaceutical formulation for topical administration comprising b220
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
EA201491870A1 (ru) Способ лечения гиперурикемии у больных подагрой с помощью галофената или галофеновой кислоты и противовоспалительного агента
FI3519050T3 (fi) Koostumuksia silmätautien hoitamiseksi

Legal Events

Date Code Title Description
FG Grant or registration